|
|
Drug Discovery--European Advances in Genomics and Proteomics (Technical Insights)Published by: Frost & Sullivan Published: Dec. 31, 2004 Table of Contents1. Executive Summary 1. Introduction 1. Introduction 2. Genomics 3. Proteomics 4. Primary Applications: Drug Discovery and Molecular Diagnostics 5. Market Trends 2. Scope and Methodology 1. Scope 2. Methodology 2. Primer on Genomics and Proteomics Technologies 1. Genomics 1. Introduction 2. SNP Profiling 3. Functional Genomics 4. Structural Genomics 5. Pharmacogenomics 6. Toxicogenomics 7. Chemical Genomics (Chemogenomics) 2. Proteomics 1. Introduction 2. Proteomics Techniques 3. Related Fields of Study 1. Glycomics and Other “Omics” 2. Systems Biology 3. Applications Analysis and Trends 1. Genomics 1. Drug Discovery 2. Molecular Diagnostics 2. Proteomics 1. Drug Discovery 2. Molecular Diagnostics 3. Antibodies as Therapeutics 4. Noteworthy Innovation at Key Academic and Government-Related Institutions 1. Analysis and Ranking of Application Segments 1. Introduction 2. Regulatory Hurdles 2. Genomics 1. DNA Chips 2. Human Epigenome Project 3. Proteomics 1. Protein Chips 2. German Research Foundation To Establish Seven New Research Centers 5. Noteworthy Innovation by Key companies 1. Genomics 1. Pharmacogenomics 2. Genome Sequencing 3. Gene Expression 4. Reverse Genomics 5. Functional Genomics 6. Applications 7. Labeling and Detection Methods 8. DNA Chips and Microarrays 9. Chemical Genomics 10. Additional Genomics Companies 2. Proteomics 1. Protein Crystallography 2. Spectroscopy 3. Antibodies for Protein Identification; Auto-Immune Research 4. Detection and Labeling 5. Protein and Antibody Expression Systems 6. Protein-Protein Interaction 7. Protein chips 8. Applications 9. Additional Proteomics Companies 3. The Other 'ics' 1. Glycomics 2. Bioinformatics 6. Regulatory and Political Factors 1. Government Guidelines and Support 1. FDA Guidelines 2. Governmental Support; Both Financial and IP Protection; Are Needed 2. Pharmaceutical Industry Response 1. Pharmaceutical Industry Reluctance 2. Fear of the New 7. Industry Trends 1. Market Trends 1. Genomics 2. Proteomics And Systems Biology 2. Enabling Technologies and Their Markets 1. Electrophoresis and Proteome Informatics 2. DNA and Protein Microarrays 3. Spectroscopy and Chromatography 4. Labs-on-a-Chip--Miniaturization Brings Higher Throughput with Less Sample 5. Multiplexing and Biomarker-Based Diagnostics Market 6. Automation 7. New Tools for Genomics 8. High-Throughput Screening Technologies Accelerate Drug Discovery 8. Technology Adoption Factor Analysis 1. Technology Drivers 1. Technology Features and Benefits 2. Adoption Drivers for Genomics and Proteomics 3. Analysis of Funding 2. Technology Restraints 1. Technology or Product Development Restraints 2. Competing Technologies and Complexity 9. Contacts and Patents 1. Contacts 1. European Companies 2. Non-European Companies 2. Patents 1. Patents--Section I 2. Patents-- Section II 10. Frost & Sullivan 2005 Science and Technology Awards 1. Technology Innovation 1. Award Description 2. Award Recipient 2. Technology Leadership 1. Award Description 2. Award Recipient 3. Product Leadership 1. Award Description 2. Award Recipient 11. Decision Support Database 1. Decision Support Database Relevant To This Study 1. Government Healthcare Expenditure 2. Private Healthcare Expenditure 3. Total Healthcare Expenditure 4. Government Biotech R&D Investments 5. Private Biotech R&D Investments 6. Pharma R&D Expenditure AbstractGenomics and Proteomics Research in Europe is ThrivingThe European Union (EU) has become a popular hub for advanced research into genomics and proteomics. This can be attributed to the significant government funding at both the national level and from individual EU agencies. Moreover, Europe houses some of the largest pharmaceutical companies that are extending their support to research programs related to genomics and proteomics, either in-house or in collaboration with smaller firms. The primary goal is to go beyond the realms of human genome sequencing and expand the list of identified proteins and genes, which will ultimately aid in understanding disease mechanisms and developing corresponding therapeutics. This Technical Insights research service analyses key developments in proteomics and genomics and its impact on the field of drug discovery and development. In addition to evaluating research trends in companies and universities in the EU, this study evaluates the important technology drivers and challenges. Participants can use this research service to identify potential collaborators, stay ahead of the competition and remain abreast of critical developments. Genomics and Proteomics Gaining Prominence as Primary Tools for Drug Discovery While the potential of genomics and proteomics is constantly growing, the most lucrative applications lie in the field of drug discovery and development and molecular diagnostics. Proteomics and genomics are expected to be key tools in target identification and validation and ultimately expanding the list of cellular targets. "New information on the molecular mechanisms responsible for disease has enhanced the identification and validation processes," says the analyst of this research. "With regard to molecular diagnostics, the expectation is that diseases with a genetic component can be treated according to specific genetic markers, medications and dosages that are optimized for individual patients." Human genomic research is accelerating as scientists seek effective therapies with the ability to target the appropriate genes for activation inhibition or replacement. The target genes are multiplying in numbers and researchers are hoping to develop treatments for a wide variety of disorders, from cystic fibrosis to cancer and cardiovascular disease. Enabling Technologies are Accelerating Progress in Genomics and Proteomics Emerging technologies such as microarrays, automation and robotics are taking genomics and proteomics research to new heights. "Weeks, if not months, were initially required to elucidate the expression of a single gene," observes the analyst. "Now, tens and thousands of genes can be studied in a single afternoon." In addition, previously time-consuming and skill-intensive assays and preparations can now be accomplished thousands of samples at a time and within a few hours. This is made possible through new computer-modelling approaches such as molecular dynamics (MD), ligand docking (LD), pharmacophore modelling (PM), homology modelling (HM) and enzyme-substrate modelling (ESM).
Since conventional technologies such as 2D gel electrophoresis pose certain limitations, development of new technologies such as isotope coded affinity tags, 2D chromatographic separation, terahertz pulsed imaging (TPI) and terahertz pulsed spectroscopy (TPS) and protein arrays are also gaining importance.
|
|
|||
|
About MarketResearch.com
|
||||